Internal Medicine, Hematology · Saint Louis, MO
NPI
1841494358
Since 2007
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4500 Forest Park Ave, Div Im Hematology, 6th Fl
Saint Louis, MO, 63108
Phone (314) 362-7216
Groups this clinician bills Medicare through
Medicare paid, 2024
$44K
2,968 services
Medicare patients, 2024
80
Average age 71
Drug cost, 2024
$6.4M
521 prescriptions
Company payments, 2025
$35K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stephen T Oh was code 36415 (venipuncture blood collection), 56 times for 43 patients. In total Stephen T Oh billed 2,968 services in 55 codes, and Medicare paid $44K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 56 | 43 | $8.65 | $484 |
| 99214 Office E&M - Established | Office | 52 | 35 | $90.44 | $4,703 |
By year: 2022 $219K for 22,655 services; 2023 $152K for 13,593 services; 2024 $44K for 2,968 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 56 | 43 | $8.65 | $484 |
Medicare prescription drug claims, 2024
In 2024, the drug Stephen T Oh prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 236 prescriptions and refills. In total Stephen T Oh wrote 521 Medicare prescriptions that cost $6.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 236 | 236 | 27 | $4.1M |
| Hydroxyurea Generic | 124 | 264 | 29 | $3,735 |
| Ojjaara Momelotinib Dihydrochloride | 28 | 28 | Under 11 | $791K |
| Anagrelide Hcl Generic | 26 | 56 | Under 11 | $2,869 |
| Ayvakit Avapritinib | 24 | 24 | Under 11 | $906K |
| Besremi Ropeginterferon Alfa-2b-Njft | 17 | 17 | Under 11 | $295K |
| Ondansetron Odt Ondansetron | 14 | 14 | Under 11 | $5.11 |
| Tasigna Nilotinib Hcl | 14 | 14 | Under 11 | $274K |
| Allopurinol Generic | 11 | 18 | Under 11 | $150 |
Brand drugs: 329 claims; generic drugs: 192 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stephen T Oh $35K ($34K in general payments such as food, travel and fees and $143 for research) from 12 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $16K.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 10 | $16K |
| Incyte Corporation INCY | 17 | $12K |
| PharmaEssentia USA Corporation 6446.TW | 3 | $6,888 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $143 |
| GlaxoSmithKline, LLC. GSK | 4 | $88.65 |
| Sobi, Inc SOBI.ST | 3 | $73.58 |
| Novo Nordisk Inc NVO | 1 | $24.53 |
| Servier Pharmaceuticals LLC | 1 | $20.29 |
| HEMA Biologics, LLC | 1 | $15.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.